Comparison of Cardiac Troponin I and T, Including the Evaluation of an Ultrasensitive Assay, as Indicators of Doxorubicin-induced Cardiotoxicity

Toxicologic Pathology

Volumn 41, Issue 8, 2013, Pages 1146-1158

  Reagan, William J ^a   York, Malcolm ^b   Berridge, Brian ^c   Schultze, Eric ^d   Walker, Dana ^e   Pettit, Syril ^f  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

Author keywords

cardiac troponin; cardiovascular system; clinical pathology; doxorubicin; rat

Indexed keywords

CARDIAC TROPONIN; CARDIOVASCULAR SYSTEM; CLINICAL PATHOLOGY; DOXORUBICIN.; RAT;

ANIMALS; BODY WEIGHT; CLINICAL CHEMISTRY TESTS; DOXORUBICIN; EATING; HEART; HEART DISEASES; HEMATOLOGIC TESTS; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TOXICITY TESTS; TROPONIN I; TROPONIN T;

DOXORUBICIN; ETOPOSIDE; RAZOXANE; TROPONIN I; TROPONIN T;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CONTROLLED STUDY; FOOD INTAKE; HEART ATRIUM; HEART INJURY; HEART MUSCLE CELL; HEART VENTRICLE; HEMATOLOGY; HISTOPATHOLOGY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84885088359     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623313482056     Document Type: Article

References (33)

1. Apple F. S. Collinson P. O. (2012). Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 58, 54–61.
2. Balazs T. Ferrans V. J. El-Hage A. Ehrreich S. J. Johnson G. L. Herman E. H. Atkinson J. C. West W. L. (1981). Study of the mechanism of hydralazine-induced myocardial necrosis in the rat. Toxicol Appl Pharmacol 59, 524–34.
3. Basit M. Bakshi N. Hashem M. Allebban Z. Lawson N. Rosman H. S. Maciejko J. J. (2007). The effect of freezing and long-term storage on the stability of cardiac troponin T. Am J Clin Pathol 128, 164–67.
4. Bergmann O. Bhardwaj R. D. Bernard S. Zdunek S. Barnabe-Heider F. Walsh S. Zupicich J. Alkass K. Buchholz B. A. Druid H. Jovinge S. Frisen J. (2009). Evidence for cardiomyocyte renewal in humans. Science 324, 98–102.
5. Berridge B. R. Pettit S. Walker D. B. Jaffe A. S. Schultze A. E. Herman E. Reagan W. J. Lipshultz S. E. Apple F. S. York M. J. (2009). A translational approach to detecting drug-induced cardiac injury with cardiac troponins: Consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute. Am Heart J 158, 21–29.
6. Bertinchant J. P. Polge A. Juan J. M. Oliva-Lauraire M. C. Giuliani I. Marty-Double C. Burdy J. Y. Fabbro-Peray P. Laprade M. Bali J. P. Granier C. de la Coussaye J. E. Dauzat M. (2003). Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings. Clin Chim Acta 329, 39–51.
7. Bertinchant J. P. Robert E. Polge A. Marty-Double C. Fabbro-Peray P. Poirey S. Aya G. Juan J. M. Ledermann B. de la Coussaye J. E. Dauzat M. (2000). Comparison of the diagnostic value of cardiac troponin I and T determinations for detecting early myocardial damage and the relationship with histological findings after isoprenaline-induced cardiac injury in rats. Clin Chim Acta 298, 13–28.
8. Bizzi A. Ceriani L. Gerundino M. Spina A. Tacconi M. T. Veneroni E. (1983). Adriamycin causes hyperlipemia as a consequence of nephrotoxicity. Toxicol Lett 18, 291–300.
9. Brady S. York M. Scudamore C. Williams T. Griffiths W. Turton J. (2010). Cardiac troponin I in isoproterenol-induced cardiac injury in the Hanover Wistar rat: Studies on low dose levels and routes of administration. Toxicol Pathol 38, 287–91.
10. Clements P. Brady S. York M. Berridge B. Mikaelian I. Nicklaus R. Gandhi M. Roman I. Stamp C. Davies D. McGill P. Williams T. Pettit S. Walker D. Turton J. (2010). Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat. Toxicol Pathol 38, 703–14.
11. Herman E. H. Lipshultz S. E. Rifai N. Zhang J. Papoian T. Yu Z. X. Takeda K. Ferrans V. J. (1998). Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity. Cancer Res 58, 195–7.
12. Herman E. H. Zhang J. Lipshultz S. E. Rifai N. Chadwick D. Takeda K. Yu Z. X. Ferrans V. J. (1999). Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17, 2237–43.
13. Herman E. H. Zhang J. Rifai N. Lipshultz S. E. Hasinoff B. B. Chadwick D. P. Knapton A. Chai J. Ferrans V. J. (2001). The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48, 297–304.
14. Hortobagyi G. N. (1997). Anthracyclines in the treatment of cancer. An overview. Drugs 54, 1–7.
15. Koh E. Nakamura T. Takahashi H. (2004). Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68, 163–7.
16. Morrow D. A. Antman E. M. (2009). Evaluation of high-sensitivity assays for cardiac troponin. Clin Chem 55, 5–8.
17. O’Brien P. J. (2006). Blood cardiac troponin in toxic myocardial injury: Archetype of a translational safety biomarker. Expert Rev Mol Diagn 6, 685–702.
18. O’Brien P. J. (2008). Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 245, 206–18.
19. Octavia Y. Tocchetti C. G. Gabrielson K. L. Janssens S. Crijns H. J. Moens A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52, 1213–25.
20. Patel V. B. Ajmal R. Sherwood R. A. Sullivan A. Richardson P. J. Preedy V. R. (2001). Cardioprotective effect of propranolol from alcohol-induced heart muscle damage as assessed by plasma cardiac troponin-T. Alcohol Clin Exp Res 25, 882–89.
21. Sabatine M. S. Morrow D. A. de Lemos J. A. Jarolim P. Braunwald E. (2009). Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: Results from TIMI 35. Eur Heart J 30, 162–69.
22. Schultze A. E. Carpenter K. H. Wians F. H. Agee S. J. Minyard J. Lu Q. A. Todd J. Konrad R. J. (2009). Longitudinal studies of cardiac troponin-I concentrations in serum from male Sprague Dawley rats: Baseline reference ranges and effects of handling and placebo dosing on biological variability. Toxicol Pathol 37, 754–60.
23. Schultze A. E. Konrad R. J. Credille K. M. Lu Q. A. Todd J. (2008). Ultrasensitive cross-species measurement of cardiac troponin-I using the Erenna immunoassay system. Toxicol Pathol 36, 777–82.
24. Seiter K. (2005). Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4, 219–34.
25. Tian Hu S. Brandle E. Zbinden G. (1983). Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-159. Pharmacology 26, 210–20.
26. Tonomura Y. Mori Y. Torii M. Uehara T. (2009). Evaluation of the usefulness of biomarkers for cardiac and skeletal myotoxicity in rats. Toxicology 266, 48–54.
27. Vacchi-Suzzi C. Bauer Y. Berridge B. R. Bongiovanni S. Gerrish K. Hamadeh H. K. Letzkus M. Lyon J. Moggs J. Paules R. S. Pognan F. Staedtler F. Vidgeon-Hart M. P. Grenet O. Couttet P. (2012). Perturbation of microRNAs in rat heart during chronic doxorubicin treatment. PLoS One 7, e40395.
28. Wallace K. B. Hausner E. Herman E. Holt G. D. MacGregor J. T. Metz A. L. Murphy E. Rosenblum I. Y. Sistare F. D. York M. J. (2004). Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 32, 106–21.
29. Wilson S. R. Sabatine M. S. Braunwald E. Sloan S. Murphy S. A. Morrow D. A. (2009). Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: Observations from the PROTECT-TIMI 30 Trial. Am Heart J 158, 386–91.
30. Yavuz Y. Yurumez Y. Ciftci I. H. Sahin O. Saglam H. Buyukokuroglu M. (2008). Effect of diphenhydramine on myocardial injury caused by organophosphate poisoning. Clin Toxicol (Phila) 46, 67–70.
31. York M. Scudamore C. Brady S. Chen C. Wilson S. Curtis M. Evans G. Griffiths W. Whayman M. Williams T. Turton J. (2007). Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat. Toxicol Pathol 35, 606–17.
32. Zhang J. Herman E. H. Robertson D. G. Reily M. D. Knapton A. Ratajczak H. V. Rifai N. Honchel R. Blanchard K. T. Stoll R. E. Sistare F. D. (2006). Mechanisms and biomarkers of cardiovascular injury induced by phosphodiesterase inhibitor III SK&F 95654 in the spontaneously hypertensive rat. Toxicol Pathol 34, 152–63.
33. Zhang J. Knapton A. Lipshultz S. E. Weaver J. L. Herman E. H. (2008). Isoproterenol-induced cardiotoxicity in Sprague-Dawley rats: Correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol Pathol 36, 277–8.